Altria
MO · What the business does, what can go wrong, and how options sellers approach it
What it does
Altria Group is a U.S. tobacco company. Its main business is selling cigarettes, led by the Marlboro brand, long the country's best-selling cigarette. It also sells smokeless tobacco and cigars, plus a smaller focus on smoke-free products such as nicotine pouches and e-vapor.
Altria sells mainly in the United States. Philip Morris International is a separate company.
How it makes money
Altria sells tobacco products to wholesalers and retailers, who sell to adult consumers. Cigarette volumes have been declining for years, so the company has relied on raising prices to protect revenue. Cigarettes are cheap to make, and strong brands give the company pricing power, so margins can be high even after heavy excise taxes. The business also needs little capital, so much of its cash can go to shareholders.
Why investors own it
Many investors own Altria for income. The company has a long history of paying out much of its earnings as dividends and buying back stock. Its brands are well established, and its cash flow has been steady even as smoking declines. Some also value its defensive, consumer-staples profile.
What can go wrong
- Cigarette volumes keep shrinking, and price increases may not offset that forever.
- Regulation, including flavor, menthol and nicotine rules, is a constant risk, and lawsuits can arise from the industry's history.
- Smoke-free products face approval hurdles, competition and illegal disposable vapes.
- The dividend is not guaranteed and depends on cash flow.
What to watch
- Cigarette shipment volumes and pricing
- Marlboro market share trends
- Progress of smoke-free products
- FDA decisions on flavors, menthol and product authorizations
- Free cash flow and the dividend payout ratio
- Litigation and enforcement against illicit vapes
Options income angle
Options on MO are typically liquid, with weekly and monthly expirations. Implied volatility tends to be relatively low for an individual stock. It usually rises around earnings and major regulatory news.
One caution for premium sellers: the stock pays a sizable regular dividend, so in-the-money short calls can be assigned early before an ex-dividend date. Premiums are also modest, so a sudden regulatory or legal headline can erase months of income.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 25, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
Altria's underlying results grew modestly in 2025, but reported earnings fell sharply. The main cause was non-cash write-downs of the NJOY e-vapor business after a U.S. import ban on its leading product. Cigarette volumes keep shrinking, and higher prices are what keep profit growing.
How the business did
- Net revenues were $23,279 million versus $24,018 million, a 3.1% decrease. Reported net earnings of $6,947 million fell 38.3%, mainly because 2024 included a gain on selling IQOS commercialization rights. Adjusted net earnings (which strip out items management sees as outside underlying operations) were $9,148 million, up 2.4%. Adjusted diluted EPS was $5.42, up 4.4%.
- Smokeable products (cigarettes and cigars) saw reported domestic cigarette shipment volume fall 10.0%, offset by higher pricing. Adjusted operating companies income (OCI, segment profit before corporate costs) was $11,064 million versus $10,922 million. Marlboro retail share was 40.5% versus 41.7%.
- Oral tobacco products had adjusted OCI of $1,835 million. The segment's retail share fell to 31.9% from 37.3% as Copenhagen and Skoal lost ground, while on! pouch shipments rose to 177.8 million from 160.3 million.
- E-vapor products reported an OCI loss of $2,297 million, including $2,128 million of impairment charges on goodwill and intangible assets.
- Operating cash flow was $9.3 billion versus $8.8 billion. Dividends paid were approximately $6,960 million. The debt-to-Consolidated EBITDA ratio was 2.0.
Risks specific to this company
- NJOY import ban: The ITC (U.S. International Trade Commission) banned imports and sales of NJOY ACE after a patent case. The ban stays in place during the company's appeal, and JUUL has filed similar claims over NJOY Daily. E-vapor goodwill still carries a value of $610 million, and a hypothetical 1% rise in the discount rate would have meant roughly $150 million more impairment.
- Illicit e-vapor: The company estimates flavored disposable e-vapor products, most of which it believes evaded regulation, are approximately 70% of the e-vapor category. It expects enforcement to come more slowly than first anticipated.
- Down-trading: Strained consumers are moving to cheaper cigarettes. Discount share of the cigarette category reached 32.9% in the fourth quarter of 2025, up 2.6 share points from a year earlier.
- Skoal trademark: Its estimated fair value exceeded carrying value by only approximately 7% ($0.3 billion). A hypothetical 1% discount-rate increase would have caused about $90 million of impairment.
- Litigation and settlements: Charges under state settlement agreements were approximately $3.0 billion in 2025. The company also faces tobacco lawsuits, patent suits and the federal racketeering case, in which the court ordered "corrective statements."
- FDA rules: The FDA proposed a cap on nicotine in cigarettes. The company expects that rulemaking to take multiple years.
What management is watching
- The Optimize & Accelerate cost program targets cumulative savings of at least $600 million by the end of 2029. Estimated pre-tax charges were raised to approximately $175 million from approximately $125 million.
- The 2028 Goals call for mid-single digits adjusted diluted EPS growth from a $4.87 base in 2022 (progress through 2025 is 3.6%). They also call for mid-single digits annual dividend growth, debt-to-Consolidated EBITDA of approximately 2.0x, and a total adjusted OCI margin of at least 60%.
- Smoke-free goals are being reassessed until the legitimate e-vapor market is clearer. The on! PLUS pouch was commercialized in the first quarter of 2026 after FDA marketing orders in December 2025.
- Settlement payments and FDA user fees are estimated at $3.0 billion on average for the next three years. Capital expenditures for 2026 are expected at $300 million to $375 million.
- Tariffs are not expected to have a material impact on costs in 2026, and management continues to monitor them.
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed October 29, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
Altria's third-quarter earnings rose on higher cigarette pricing and stronger income from its ABI stake, even as cigarette and moist smokeless tobacco volumes kept falling. Reported net earnings attributable to Altria were $2,518 million, up 6.0%, and diluted EPS was $1.51. Management says shoppers under inflation pressure are trading down to discount brands and moving to smoke-free products, but that these trends have not had a material adverse impact on results.
How the business did
- Quarter: Net revenues were $6,132 million versus $6,072 million a year earlier. Adjusted net earnings (which strip out items management views as unusual) were $2,547 million, up 4.2%, with adjusted diluted EPS of $1.52.
- Year to date: Reported net earnings were $6,999 million, up 20.1%, helped because 2025 included a non-cash goodwill impairment on the e-vapor business. Adjusted diluted EPS for the nine months was $4.33, up 5.1%.
- Cigarettes: Smokeable products operating companies income (OCI, the segment's profit before corporate costs) was $3,053 million, up 3.8%. Higher pricing of $290 million and higher refunds of taxes and duties paid on imported cigarettes helped, offset by a $254 million revenue hit from lower volume and a shift toward discount brands. Domestic cigarette shipments fell 2.9%, and discount brands took 34.1% of the category.
- Oral tobacco: OCI fell to $434 million, down 5.4%. Copenhagen and Skoal volumes fell, while on! nicotine pouch volume rose 13.3%. Nicotine pouches reached 61.2% of the U.S. oral tobacco category.
- Cash and capital return: Nine-month operating cash flow was $6,151 million versus $6,019 million. Dividends paid were $5,330 million. The company repaid $0.5 billion of notes in September 2026, and its debt-to-Consolidated EBITDA ratio was 1.9.
What management is watching
- Dividend: The Board raised the quarterly dividend 4.7% to $1.11 per share. The stated goal is mid-single digits dividend growth annually through 2028.
- Consumer and regulatory pressure: Management points to inflation, discount-brand share, illicit flavored disposable e-vapor products and slow FDA action. In September 2026, Helix, NJOY and trade partners sued the FDA over missed 180-day review deadlines, and the court stayed the case to allow FDA rulemaking. In August 2026 the FDA granted marketing orders for additional on! flavors.
- Spending and fixed costs: The company is moving smokeless manufacturing from Nashville to Hopkinsville, Kentucky, with $87 million of exit and implementation costs over nine months. State settlement payments and FDA user fees are estimated at $3.0 billion on average for the next three years.
- Asset write-down risk: The e-vapor goodwill carried $610 million at December 31, 2025, and the Skoal trademark's fair value exceeded its carrying value by approximately 7% ($0.3 billion). Management says further non-cash impairments could be material. A hypothetical 1% rise in the discount rate would have meant charges of approximately $150 million and approximately $90 million, respectively, in the 2025 tests.
- Measures it highlights: Adjusted OCI, adjusted EPS and debt-to-Consolidated EBITDA. The MD&A does not give a full-year earnings forecast.
Follow MO in Kortex
The Kortex app shows MO's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.